Survodutide Phase 3 Cardiovascular Safety Trial Marked Completed

On August 11, 2026, the clinical trial registry status for survodutide (BI 456906) was updated to completed. The trial, titled "A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity," is registered as NCT06077864 and also known as SYNCHRONIZE-CVOT. It is a Phase 3 study designed to evaluate cardiovascular safety in participants with overweight or obesity. The registry entry lists the trial status as completed as of the date given. Survodutide remains classified as an unapproved compound currently in research use. This update reflects only the change in trial status recorded in the registry. No results, outcomes, or safety findings have been reported alongside this status change. The trial identifier and phase are documented facts drawn directly from the registry listing. Readers should note that a completed status refers to the conclusion of the study's active phase as recorded, not to any specific conclusion about cardiovascular safety. Further details about design, population, and endpoints are available through the official registry listing linked with this trial. For additional background on survodutide, including its current regulatory classification and research context, readers can consult the compound overview.